CY1110133T1 - Θεραπευτικος παραγων υπερλιπαιμιας που περιλαμβανει πιταβαστατινες και εικοσαπενταενοϊκο οξυ - Google Patents
Θεραπευτικος παραγων υπερλιπαιμιας που περιλαμβανει πιταβαστατινες και εικοσαπενταενοϊκο οξυInfo
- Publication number
- CY1110133T1 CY1110133T1 CY20101100490T CY101100490T CY1110133T1 CY 1110133 T1 CY1110133 T1 CY 1110133T1 CY 20101100490 T CY20101100490 T CY 20101100490T CY 101100490 T CY101100490 T CY 101100490T CY 1110133 T1 CY1110133 T1 CY 1110133T1
- Authority
- CY
- Cyprus
- Prior art keywords
- acid
- viscentagenic
- pitavastatines
- hyperployees
- therapy including
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η παρούσα εφεύρεση αφορά θεραπευτικό παράγοντα υπερλιπαιμίας που περιλαμβάνει πιταβαστατίνες και εικοσαπενταενοϊκό οξύ ή παράγωγο εστέρα αυτού, ως δραστικά συστατικά. Σύμφωνα με την παρούσα εφεύρεση, παρέχονται θεραπευτικοί παράγοντες υπερλιπαιμίας τύπου llb και τύπου IV που έχουν εξαιρετικό αποτέλεσμα μείωσης χοληστερόλης και τριγλυκεριδίων στο αίμα.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/780,640 US7022713B2 (en) | 2004-02-19 | 2004-02-19 | Hyperlipemia therapeutic agent |
EP05710692A EP1715865B9 (en) | 2004-02-19 | 2005-02-18 | Hyperlipemia therapeutic agent comprising pitavastatins and eicosapentaenoic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1110133T1 true CY1110133T1 (el) | 2015-01-14 |
Family
ID=34860884
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20101100490T CY1110133T1 (el) | 2004-02-19 | 2010-06-03 | Θεραπευτικος παραγων υπερλιπαιμιας που περιλαμβανει πιταβαστατινες και εικοσαπενταενοϊκο οξυ |
Country Status (15)
Country | Link |
---|---|
US (2) | US7022713B2 (el) |
EP (1) | EP1715865B9 (el) |
JP (1) | JP5474276B2 (el) |
KR (1) | KR101376449B1 (el) |
CN (1) | CN100475208C (el) |
AT (1) | ATE460164T1 (el) |
CY (1) | CY1110133T1 (el) |
DE (1) | DE602005019856D1 (el) |
DK (1) | DK1715865T3 (el) |
ES (1) | ES2342609T3 (el) |
HK (1) | HK1098953A1 (el) |
PL (1) | PL1715865T3 (el) |
PT (1) | PT1715865E (el) |
SI (1) | SI1715865T1 (el) |
WO (1) | WO2005079797A2 (el) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060276486A1 (en) * | 2003-04-17 | 2006-12-07 | Kowa Co., Ktd. | Lklf/klf2 gene expression promoter |
US7022713B2 (en) * | 2004-02-19 | 2006-04-04 | Kowa Co., Ltd. | Hyperlipemia therapeutic agent |
JP5069448B2 (ja) * | 2006-02-07 | 2012-11-07 | 持田製薬株式会社 | 脳卒中再発予防用組成物 |
CA2571462C (en) * | 2006-02-07 | 2013-08-13 | Mochida Pharmaceutical Co., Ltd. | Composition for preventing recurrence of stroke |
US8784886B2 (en) * | 2006-03-09 | 2014-07-22 | GlaxoSmithKline, LLC | Coating capsules with active pharmaceutical ingredients |
US7728697B2 (en) * | 2006-09-26 | 2010-06-01 | Mg Materials Corporation | Systems and methods for electrically reducing ferroelectric materials to increase bulk conductivity |
US20080085911A1 (en) * | 2006-10-10 | 2008-04-10 | Reliant Pharmaceuticals, Inc. | Statin and omega-3 fatty acids for reduction of apo-b levels |
US20100119600A1 (en) * | 2007-06-01 | 2010-05-13 | Joar Opheim | Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof |
EP2308493A4 (en) * | 2008-07-07 | 2013-05-01 | Mochida Pharm Co Ltd | ENHANCING OR THERAPEUTIC AGENT FOR DYSLIPIDEMIA |
EP4137128A1 (en) | 2008-09-02 | 2023-02-22 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and a statin, and methods of using same |
PT2395991E (pt) * | 2009-02-10 | 2013-09-03 | Amarin Pharmaceuticals Ie Ltd | Utilização de éster etílico de ácido eicosapentaenóico para tratamento de hipertrigliceridemia |
LT3278665T (lt) | 2009-04-29 | 2020-12-10 | Amarin Pharmaceuticals Ireland Limited | Stabili farmacinė kompozicija ir jos panaudojimo būdai |
EP3791880A1 (en) | 2009-04-29 | 2021-03-17 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising epa |
ES2856959T3 (es) | 2009-06-15 | 2021-09-28 | Amarin Pharmaceuticals Ie Ltd | Composiciones y métodos para el tratamiento del ictus en un sujeto en terapia simultánea con estatina |
RU2012116079A (ru) | 2009-09-23 | 2013-10-27 | АМАРИН КОРПОРЕЙШН ПиЭлСи | Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина и способы ее применения |
EP2488022B1 (en) * | 2009-10-16 | 2018-01-10 | Mochida Pharmaceutical Co., Ltd. | Compositions |
US20140127289A1 (en) | 2010-11-29 | 2014-05-08 | Armarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
DK3363433T3 (da) | 2012-06-29 | 2021-03-08 | Amarin Pharmaceuticals Ie Ltd | Fremgangsmåder til reduktion af risikoen for en kardiovaskulær begivenhed i et individ i statinbehandling ved anvendelse af eicosapentaensyreetylester |
CN102824636A (zh) * | 2012-08-15 | 2012-12-19 | 四川大学 | 一种含他汀类药物和多不饱和脂肪酸的药物组合物及其用途 |
US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
EP3738586A1 (en) | 2013-10-30 | 2020-11-18 | Patheon Softgels Inc. | Enteric soft capsules comprising polyunsaturated fatty acids |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
CA2950444C (en) * | 2014-06-26 | 2021-01-12 | Banner Life Sciences Llc | Enhanced bioavailability of polyunsaturated fatty acids |
US9895333B2 (en) | 2014-06-26 | 2018-02-20 | Patheon Softgels Inc. | Enhanced bioavailability of polyunsaturated fatty acids |
WO2016026139A1 (zh) * | 2014-08-22 | 2016-02-25 | 财团法人国防教育研究基金会 | 用于治疗非酒精性脂肪肝疾病的药物及应用 |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US10600502B2 (en) | 2016-12-20 | 2020-03-24 | Astrazeneca Uk Ltd. | Systems and methods for dispensing a statin medication over the counter |
US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
PT4056176T (pt) | 2018-09-24 | 2024-05-27 | Amarin Pharmaceuticals Ie Ltd | Métodos de redução do risco de eventos cardiovasculares num indivíduo |
US20220008519A1 (en) | 2020-07-09 | 2022-01-13 | Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) | Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho |
KR20240012390A (ko) | 2021-04-21 | 2024-01-29 | 애머린 파마슈티칼스 아일랜드 리미티드 | 심부전의 위험을 감소시키는 방법 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2569746B2 (ja) * | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
GB8819110D0 (en) * | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
US5861399A (en) * | 1996-07-17 | 1999-01-19 | Heart Care Partners | Methods and compositions for the rapid and enduring relief of inadequate myocardial function |
SK285210B6 (sk) * | 1996-10-11 | 2006-09-07 | Scarista Limited | Farmaceutický prípravok na liečenie schizofrénie a použitie oleja obsahujúceho kyselinu eikozapentaenovú alebo stearidonovú, alebo ich kombináciu na prípravu tohto liečiva |
US6083497A (en) * | 1997-11-05 | 2000-07-04 | Geltex Pharmaceuticals, Inc. | Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers |
US6982251B2 (en) * | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
KR20040026705A (ko) * | 2001-08-16 | 2004-03-31 | 테바 파마슈티컬 인더스트리즈 리미티드 | 스타틴의 칼슘 염 형태의 제조 방법 |
JP2005538148A (ja) * | 2002-08-26 | 2005-12-15 | リピド サイエンスィズ インコーポレイテッド | 脱脂タンパク質粒子を使用したアルツハイマー病治療 |
US7022713B2 (en) * | 2004-02-19 | 2006-04-04 | Kowa Co., Ltd. | Hyperlipemia therapeutic agent |
-
2004
- 2004-02-19 US US10/780,640 patent/US7022713B2/en not_active Expired - Lifetime
-
2005
- 2005-02-18 DE DE602005019856T patent/DE602005019856D1/de active Active
- 2005-02-18 EP EP05710692A patent/EP1715865B9/en not_active Not-in-force
- 2005-02-18 DK DK05710692.4T patent/DK1715865T3/da active
- 2005-02-18 JP JP2006525561A patent/JP5474276B2/ja not_active Expired - Fee Related
- 2005-02-18 SI SI200531022T patent/SI1715865T1/sl unknown
- 2005-02-18 WO PCT/JP2005/003092 patent/WO2005079797A2/en not_active Application Discontinuation
- 2005-02-18 CN CNB2005800053563A patent/CN100475208C/zh not_active Expired - Fee Related
- 2005-02-18 PL PL05710692T patent/PL1715865T3/pl unknown
- 2005-02-18 KR KR1020067016099A patent/KR101376449B1/ko not_active IP Right Cessation
- 2005-02-18 AT AT05710692T patent/ATE460164T1/de active
- 2005-02-18 ES ES05710692T patent/ES2342609T3/es active Active
- 2005-02-18 PT PT05710692T patent/PT1715865E/pt unknown
- 2005-12-05 US US11/293,217 patent/US7776881B2/en not_active Expired - Fee Related
-
2007
- 2007-05-28 HK HK07105572.8A patent/HK1098953A1/xx not_active IP Right Cessation
-
2010
- 2010-06-03 CY CY20101100490T patent/CY1110133T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
PL1715865T3 (pl) | 2010-09-30 |
KR101376449B1 (ko) | 2014-03-19 |
US7022713B2 (en) | 2006-04-04 |
WO2005079797A2 (en) | 2005-09-01 |
EP1715865B1 (en) | 2010-03-10 |
CN1921860A (zh) | 2007-02-28 |
US7776881B2 (en) | 2010-08-17 |
PT1715865E (pt) | 2010-04-01 |
JP5474276B2 (ja) | 2014-04-16 |
ES2342609T3 (es) | 2010-07-09 |
US20060111437A1 (en) | 2006-05-25 |
HK1098953A1 (en) | 2007-08-03 |
EP1715865B9 (en) | 2010-12-15 |
DK1715865T3 (da) | 2010-05-10 |
EP1715865A2 (en) | 2006-11-02 |
KR20060109988A (ko) | 2006-10-23 |
CN100475208C (zh) | 2009-04-08 |
JP2007523049A (ja) | 2007-08-16 |
US20050187292A1 (en) | 2005-08-25 |
SI1715865T1 (sl) | 2010-08-31 |
DE602005019856D1 (de) | 2010-04-22 |
ATE460164T1 (de) | 2010-03-15 |
WO2005079797A3 (en) | 2006-05-11 |
EP1715865B8 (en) | 2010-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1110133T1 (el) | Θεραπευτικος παραγων υπερλιπαιμιας που περιλαμβανει πιταβαστατινες και εικοσαπενταενοϊκο οξυ | |
AR109605A2 (es) | Método para tratar enfermedades vasculares periféricas, composición y utilización | |
EA200800356A1 (ru) | Лечение ингибиторами абсорбции холестерина на основе азетидинона и омега-3 жирными кислотами и их комбинированным препаратом | |
EA200701229A1 (ru) | Омега-3 жирные кислоты и дислипидемический агент для липидной терапии | |
TR201907874T4 (tr) | Düşük sülfat fukanlar kullanarak fibröz yapışmaları ya da inflamatuar hastalıkları inhibe etmeye yönelik farmasötik kompozisyonlar ve yöntemler. | |
WO2007041398A3 (en) | Treatment of cancer with specific rxr agonists | |
SMT201300095B (it) | Uso dell'estere etilico dell'acido eicosapentaenoico per trattare l'ipertrigliceridemia | |
CY2014023I2 (el) | Συνδυασμοι και τροποι χορηγησης θεραπευτικων παραγοντων και θεραπεια συνδυασμου | |
CY1112259T1 (el) | Συνθεσεις οι οποιες περιλαμβανουν ορνιθινη και φαινυλοξικο ή φαινυλοβουτυρικο για αντιμετωπιση ηπατικης εγκεφαλοπαθειας | |
NO20065368L (no) | Terapeutiske blandinger inneholdende minst et pyrrolobenzodiazepinderivat og fludarabin | |
EA200900155A1 (ru) | Модуляторы фармакокинетических свойств лекарственных средств | |
MXPA05006670A (es) | Administracion de capsaicinoides. | |
ATE540690T1 (de) | Insulinkombinationen | |
CY1117174T1 (el) | ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ | |
CY1114760T1 (el) | Θεραπευτικη αγωγη αθηροσκληρωσης | |
WO2007130419A3 (en) | Histone deacetylase inhibitors for the treatment of neurodegeneration | |
WO2008027880A3 (en) | Strontium-based treatment of otosclerosis | |
CO5690571A2 (es) | Combinacion sinergica que comprende roflumilas y (r,r)-formoterol | |
PT1220676E (pt) | Prevencao do cancro colorrectal | |
ME00489B (me) | NOVA SINERGIČKA KOMBINACIJA KOJA UKLJUČUJE ROFLUMILAST l FERMOTEROL | |
UY30557A1 (es) | Tratamiento y prevencion de la fibrosis intestinal | |
WO2007077454A3 (en) | A therapeutic composition comprising an inhibitor of an hsp 90 protein | |
WO2008064138A3 (en) | Personalized therapeutic treatment process | |
CR8584A (es) | Piperazinas derivadas de urea para el tratamiento de la endometrosis | |
AR067351A1 (es) | Combinacion de picotamida con nafronil |